A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A danish ovarian study group trial (DACOVA)

Gynecologic Oncology

Volumn 49, Issue 1, 1993, Pages 30-36

  Bertelsen, K ^a   Jakobsen, A ^a   Stroyer I ^a   Nielsen, K ^a   Sandberg, E ^a   Andersen, J E ^a   Ahrons, S ^a   Nyland, M ^a   Pedersn, P Hjortkjær ^a   Larsen, G ^a   Rasmussen, P ^a   Kiaer H ^a   Bichel, P ^a   Jacobsen, M ^a   Holund B ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0027276217     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1993.1081     Document Type: Article

References (15)

1. Bertelsen, K., Jakobsen, A., Andersen, J. E., Ahrons, S., Hjortkjær Pedersen, P., Kiær, H., Arffmann, E., Bichel, P., Boes-tofte, E., Stroyer Christophersen, I., Gregersen, E., Kern Hansen, M., Hound, B., Jacobsen, M., Kaalund Jensen, H., Love Jepsen, F., Larsen, G., Sandberg Nielsen, E., Nyland, M., Olsen, J., Panduro, J., Rank, F., Seil, A., and Sogaard, H. A randomized study of cyclophosphamide and m-platinum with or without doxorubicin in advanced ovarian carcinoma, Gynecol. Oncol. 28, 161-169 (1987).
2. Gruppo Interregionale Cooperativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer, Lancet 2, 353-359 (1987).
3. Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., and Mortel, R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study, J. Clin. Oncol. 7, 457-465 (1989).
4. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A Meta-analysis, J. Clin. Oncol. 9, 1668-1674 (1991).
5. Conte, P. F., Bruzzone, M., Chiara, S., Sertoli, M. R., Daga, M. G., Rubagotti, A., Conio, A., Ruvolo, M., Rosso, R., Santi, L., Carnino, F., Cottini, M., Mossetti, C., Guercio, E., Gatti, M., Siliquini, P. N., Prelato, M. L., Durando, C., Giaccone, G., Calciati, A., Farinini, D., Centonze, M., Rugiati, S., Parodi, G., Messineo, M., Storace, A., Bernardini, G., Misurale, F., Alessandri, S., Casini, M., Ragni, N., Foglia, G., Bentivoglio, G., and Pescetto, G. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer, J. Clin. Oncol. 4, 965-971 (1986).
6. Hernadi, Z., Juhashz, B., Poka, R., and Lampe, L. G. Randomized trial comparing combinations of cyclophosphamide and c¿s-platinum without or with doxorubicin or 4-epi-doxorubicin in the treatment of advanced ovarian cancer, Int. J. Gynecol. Obstet. 27, 199-204 (1988).
7. Serov, S. F., and Scully, R. E. Histological typing of ovarian tumours: International classification of tumours no. 9. Genova World Health Organization Genova, Vol. 9, pp. 17-57 (1973).
8. Bertelsen, K., Htflund, B., and Andersen, J. E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer, Int. J. Gynecol. Cancer 3, 72-79 (1993).
9. Hakes, T. B., Chalas, E., Hoskins, W. J., Jones, W. B., Markman, M., Rubin, S. C., Chapman, D. C., Almadrones, L., and Lewis, J. L. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma, Gynecol. Oncol. 45, 284-289 (1992).
10. Jacobs, A. J., Sommers, G. M., Homan, S. M-, Camel, H. M., Axelrod, J. H., Kao, M-S., Galakatos, A. E., Parham, J., and Lippmann, L. Therapy of ovarian carcinoma: The relationship of dose level and treatment intensity to survival, Gynecol. Oncol. 31, 233-245 (1988).
11. Levin, L., and Hryniuk, W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma, J. Clin. Oncol. 5, 756-767 (1987).
12. Ozols, R. F., Ostchega, Y., Curt, G., and Young, R. High-dose carboplatin in refractory ovarian cancer patients, J. Clin. Oncol. 5, 197-201 (1987).
13. Kaye, S. B., Lewis, C. R., Paul, J., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M-, Rankin, E. M., Cassidy, J., Davis, J. A., Reed, N. S., Crawford, S. M., Mac Lean, A., Swapp, G. A., Sarkar, T. K., Kennedy, J. H., and Symonds, R. P. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer, Lancet 340, 329-333 (1992).
14. McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., and Clarke-Pearson, D. L. A phase III trial of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer, Proc. Am. Soc. Clin. Oncol. 11, 226 (1992).
15. Nardi, M., Cognetti, F., Pollera, C. F., Giulia, M. D., Lombardi, A., Atlante, G., and Calabresi, F. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: A phase II study, J. Clin-Oncol. 6, 1036-1041 (1990).